New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 14, 2013
20:23 EDTRHHBY, ALXNAlexion's price may be more than Roche would be willing to pay, Reuters says
A Roche (RHHBY) bid for Alexion (ALXN) would mark an attempt by Roche to diversify beyond its core cancer competencies through acquisitions but Alexion's valuation may be more than Roche would be willing to pay, says Reuters. Reference Link
News For ALXN;RHHBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 23, 2014
13:23 EDTRHHBYTetraphase said to explore sale, Bloomberg reports
Subscribe for More Information
November 20, 2014
07:09 EDTALXNAlexion management to meet with Deutsche Bank
Subscribe for More Information
November 19, 2014
10:28 EDTALXNAlexion management to meet with Deutsche Bank
Subscribe for More Information
08:03 EDTRHHBYPTC to receive $10M milestone payment from Roche as SMA program advances
Subscribe for More Information
07:52 EDTRHHBYInforma Business Information to hold a conference
Subscribe for More Information
November 18, 2014
14:59 EDTRHHBYRanbaxy sues FDA for rescinding approval of Nexium, Valcyte copies, Reuters says
Subscribe for More Information
11:22 EDTRHHBYTeva patent victory over Warner Chilcott, Roche affirmed
The U.S. Court of Appeals for the Federal Circuit ruled that a district court was correct to grant summary judgment to Teva (TEVA) in a patent dispute with Warner Chilcott and Roche (RHHBY) over patents related to osteoporosis drug risedronate.
07:52 EDTALXNFDA Drug Safety & Risk Management Advisory Committee to hold a meeting
The Committee discusses the risk management of Alexion Pharmaceuticals' Eculizumab (Soliris) is a meeting being held at FDA Silver Spring, Maryland offices on November 18 at 9 am. Webcast Link
November 17, 2014
05:30 EDTRHHBYInovio, Roche terminate collaboration for INO-5150
Subscribe for More Information
November 16, 2014
13:04 EDTALXNAlexion says data supports effectiveness of sustained Soliris treatment in aHUS
Subscribe for More Information
November 14, 2014
14:53 EDTRHHBYCVS Express Scripts implementing drug price controls, says Cleveland Research
Cleveland Research believes that CVS (CVS) and Express scripts are implementing rebates and price controls on drug. The firm expects the companies to increase their focus on controlling durg prices next year, and adds that they have already itnroduced prior authorization criteria for hepatitis drug. Publicly traded drug companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Makers of hepatits c drugs include AbbVie (ABBV) and Gilead (GILD),
13:27 EDTRHHBYRoche reports FDA nod for Avastin in platinum-resistant recurrent ovarian cancer
Subscribe for More Information
November 12, 2014
11:17 EDTRHHBYLeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information
07:22 EDTRHHBYAssociation of Molecular Pathology is holding annual meeting
2014 Annual Meeting of AMP is being held in National Harbor, Maryland on November 12-15.
November 11, 2014
15:43 EDTRHHBYLeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information
November 10, 2014
16:07 EDTRHHBYUBS to hold a conference
UBS European Conference is being held in London, England on November 11-12.
15:54 EDTALXNAmerican Society of Nephrology to hold a conference
Subscribe for More Information
09:20 EDTALXNJPMorgan biotech analyst to hold an analyst/industry conference call
U.S. SMid Biotech Analyst Rama, along with Key Opinion Leader Dr. Hickman Simmons from Vanderbilt University, discuss Alexion Pharmaceuticals' Asfotase Alfa and Hypophosophatasia on an Analyst/Industry conference call to be held on November 11 at 11 am.
06:31 EDTALXNAlexion announces planned retirement of co-founder, COO Stephen Squinto
Alexion announced the planned retirement of company co-founder Stephen Squinto, effective January 1, 2015. Squinto currently serves as Executive Vice President, Chief Global Operations Officer. He co-founded Alexion in 1992 with Leonard Bell, M.D., the Company’s principal founder and current Chairman and Chief Executive Officer.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use